Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
about
Phosalone-induced inflammation and oxidative stress in the colon: Evaluation and treatmentNeutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel diseaseTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesIntestinal inflammation and the diet: Is food friend or foe?Nanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsRole of soluble triggering receptor expressed on myeloid cells in inflammatory bowel diseaseThe selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in miceMNK kinases regulate multiple TLR pathways and innate proinflammatory cytokines in macrophages.A genetic model of chronic rhinosinusitis-associated olfactory inflammation reveals reversible functional impairment and dramatic neuroepithelial reorganization.Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.Nanobodies as novel agents for cancer therapy.The clinical application of etanercept in Chinese patients with rheumatic diseases.Meta-analysis: polymorphisms in TNF-alpha gene promoter and Crohn's disease.Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.Anti-TNF-alpha therapies in systemic lupus erythematosusSafety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: a pilot studyRegulation of intestinal regeneration: new insights.Synthesis of novel tylophorine derivatives and evaluation of their anti-inflammatory activityIntegrin-linked kinase modulates lipopolysaccharide- and Helicobacter pylori-induced nuclear factor κB-activated tumor necrosis factor-α production via regulation of p65 serine 536 phosphorylation.Immunotherapeutic approaches to inflammatory bowel diseases.Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature.The biosynthesis characteristics of TTP and TNF can be regulated through a posttranscriptional molecular loopNew treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.Oral aspects of Crohn's disease.Multiple roles for tumor necrosis factor-alpha and lymphotoxin alpha/beta in immunity and autoimmunity.Review article: biological agents in the treatment of Crohn's disease.Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathwayTransgenic mice rich in endogenous omega-3 fatty acids are protected from colitisRecent progress in ankylosing spondylitis treatment.Sjogren's syndrome: evolving therapies.Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides.Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !?Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis.Anti-TNF-alpha therapy for sight threatening uveitis.Cytokine disturbances in systemic lupus erythematosus.Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.Novel biologic therapies for psoriasis.
P2860
Q24658611-0C5115C1-B0DF-478A-BD36-3B9636DF69DBQ24669692-2EDA9ABB-36EF-45BD-9482-0825BF273659Q24806367-D83802F9-40DC-4F14-8A08-90450378CA2EQ26765223-D1674B54-5717-4B9A-9B2A-6332D8194B47Q26777400-5CFD40C9-6BF7-4EDC-99E4-1B52A6759859Q26785537-DA86A4F5-BFD1-4AE9-88F3-327DA89790CFQ28242852-A7E430E0-26CE-4298-8BB5-25AA71793DCEQ28487329-29CE4735-B4DE-4AA7-B539-680DE9087D79Q30445072-0924069F-90E2-4D01-A2EC-A86A65E42930Q30479072-00B7D8ED-F8FF-4E58-A67A-899DB48108D4Q30718083-38D122AC-BC9D-4D6E-9A50-E98D37648B9EQ30778309-1DE37849-00F3-4122-BA29-FD2065084F4CQ33372242-1B18B405-CD65-45EF-AEBA-5306B48E03D2Q33574000-4943F652-0951-4C99-B2C4-694A8EC05B9FQ33691577-3DECB53D-7856-4B07-B183-9196292D3378Q33756929-2B5DBCD5-42CD-48F8-AC27-A38E4984C3DFQ33904308-073505D3-665D-48F9-B996-77315F4A2277Q33960066-A9981482-5800-4084-AAF5-12A13A087A48Q34034566-27735C4C-0324-4062-B16D-C0C1672C69DBQ34071941-D2D8DB83-18D1-4EEE-9F60-3B1AEFB9AD5DQ34162687-16575F2C-1BAE-48A9-BDFE-9BB140387C88Q34283506-AC986EEB-A5AF-4580-B493-A133C8A76614Q34451989-B444458E-C5AE-4F66-9839-4D3293AA5813Q34454532-907680CD-C181-4F27-AD2D-CA5B2898B269Q34536989-A2674EE2-0EC4-4E6A-88BB-FFD8BA265FA8Q34560574-3F2A9BCE-BF70-4EBB-B4F3-B55CCB911E9AQ34713611-C3082023-1A8E-43E2-91B3-E0BBF8BC0FBFQ34731168-EEF44D59-9242-42DF-BFFC-FC5667079CADQ34799343-669E409D-98F0-446D-AC16-BF3494920544Q34939962-E3F20012-1AAF-43AF-9597-6DA0B13F9633Q34983954-B9538A7B-4CF4-435B-8FF9-5499A1B1679CQ35040745-286BAB7B-3A23-4B8C-A0DA-88B16516D929Q35056070-D33B6F0D-CF74-4C7C-B601-573E02E25D3BQ35164736-4C0F930A-2D18-4DD5-927F-71F5CB6DC283Q35549383-51788E3C-3B93-4F10-A0C3-855643710526Q35579230-E66AC8DA-EEEB-4535-8AFC-129265BCB132Q35593155-58C5BF06-6FE6-45B8-901D-08D696D25420Q35617573-63889FC6-C74C-4F43-8BDD-56458DD0D2D3Q35750016-93404735-715A-48F3-A13E-32E75CD4FF68Q35790897-BA483181-658D-4A2F-ADAC-2BDB308F5854
P2860
Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Antitumor necrosis factor ther ...... clinical results, and safety.
@ast
Antitumor necrosis factor ther ...... clinical results, and safety.
@en
type
label
Antitumor necrosis factor ther ...... clinical results, and safety.
@ast
Antitumor necrosis factor ther ...... clinical results, and safety.
@en
prefLabel
Antitumor necrosis factor ther ...... clinical results, and safety.
@ast
Antitumor necrosis factor ther ...... clinical results, and safety.
@en
P2860
P1476
Antitumor necrosis factor ther ...... clinical results, and safety.
@en
P2093
Hanauer SB
Sandborn WJ
P2860
P304
P356
10.1097/00054725-199905000-00008
P577
1999-05-01T00:00:00Z